Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.56) by 19.64 percent. This is a 60.87 percent increase over losses of $(1.15) per share from the same period last year. The company reported quarterly sales of $20.000 million which beat the analyst consensus estimate of $9.286 million by 115.38 percent.